PHARMACEUTICAL INDUSTRY ANALYSIS, EXTERNAL ENVIRONMENT, AND TECHNOLOGICAL ASSESSMENT FOR THE DEVELOPMENT OF AN ACQUISITION STRATEGY (NOVAVAX)

BY: JESSICA FREITAS & MILUSKA MOGROVEJO
INDUSTRY MARKET SEGMENT- RESPIRATORY/ANTI-INFECTION

• Market Segments include Cardiovascular, Central Nervous System, Internal Medicine, Oncology, Respiratory/Anti-Infectives, Consumer Products, and Other.

• Anti-Infectives include Antibiotics, Antivirals and Vaccines, while Respiratory includes drugs that are medicines for conditions and diseases relating to the lungs and/or breathing.
TOP 5 COMPETITORS (2012)

• Johnson & Johnson: Remicade (Rheumatoid Arthritis), Velcade (Multiple Myeloma and Mantle Cell Lymphoma); Risperdal Consta (Schizophrenia)

• Pfizer: Lyrica (Epilepsy), Lipitor (LDL cholesterol reduction), Enbrel (Rheumatoid, Juvenile Rheumatoid and Psoriatic Arthritis)

• Novartis AG: Gleevec (Chronic Myeloid Leukemia) Diovan/Co-Diovan (Hypertension), Lucentis, (Age-related macular degeneration) Sandostatin (Acromegaly)

• Roche: MabThera/Rituxan (non-Hodgkin’s Lymphoma), Herceptin (HER2-positive Breast Cancer), Avastin (Colorectal Cancer)

• Bayer AG: Betaferon (Multiple Sclerosis), Kogenate (Hemophilia), Nexavar (Kidney/Liver Cancer)
MERCK COMPETITOR, PHARMACEUTICAL INDUSTRY TOTAL SALES ($B) (2012)

Industry Attractiveness uses 15 different criteria to determine whether investment in an Industry is wise.¹

- The best-case scenario is to have a total score of 150 as it suggests that a company can handle all of the difficult forces.²
- Pharmaceutical Industry scored a 89.
- Biotechnology Industry scored a 103.
- Respiratory/Anti-Infectives Segment scored a 104.

ENVIRONMENTAL THREATS AND OPPORTUNITIES PROFILE: MERCK & CO, INC. RESPIRATORY/ANTI-INFECTIVES SEGMENT (2013)

Most Impactful Threats:
- Competition
- Spirit/Ethics

Most Impactful Opportunities
- Technology
- Social
ENVIRONMENTAL THREATS AND OPPORTUNITIES PROFILE (ETOP): MERCK, RESPIRATORY/ANTI-INFECTIVES SEGMENT (2013)

<table>
<thead>
<tr>
<th>Factors</th>
<th>Impact of Factor</th>
<th>Importance of Factor</th>
<th>Environmental Threat/Opportunity</th>
<th>Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Competition</td>
<td>-3</td>
<td>6</td>
<td>-18</td>
<td>1</td>
</tr>
<tr>
<td>Spirit / Ethics</td>
<td>-4</td>
<td>4</td>
<td>-16</td>
<td>2</td>
</tr>
<tr>
<td>Politics</td>
<td>-1</td>
<td>3</td>
<td>-3</td>
<td>3</td>
</tr>
<tr>
<td>Ecology</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Energy</td>
<td>1</td>
<td>7</td>
<td>7</td>
<td>5</td>
</tr>
<tr>
<td>Economics</td>
<td>3</td>
<td>6</td>
<td>18</td>
<td>6</td>
</tr>
<tr>
<td>International</td>
<td>4</td>
<td>7</td>
<td>28</td>
<td>7</td>
</tr>
<tr>
<td>Social</td>
<td>4</td>
<td>8</td>
<td>32</td>
<td>8</td>
</tr>
<tr>
<td>Technology</td>
<td>5</td>
<td>10</td>
<td>50</td>
<td>9</td>
</tr>
</tbody>
</table>

Total ETOP Score = 102

Impact is ranked from -5 (strongly negative) to +5 (strongly positive).
Importance if ranked from 1 (unimportant) to 10 (very important).

Comments: The Respiratory/Anti-Infective Market Segment is growing based on new applications of Technology to create innovative products addressing anti-biotic resistant diseases. The rise in elderly patients and access to emerging country markets as Social Factors open new opportunities for market expansion. Issues relating to FDA approval and ethical concerns over drug trials and applications of stem cell research present possible road blocks in the development of the Segment. The dilution of the Competition in the Market Segment mitigates the impact of that factor. Ultimately innovative uses of Technology to address issues raised by Social and International Factors will put companies like Merck ahead in the Market Segment.

TECHNOLOGY IN THE PHARMACEUTICAL INDUSTRY

- Genomics
- Biotechnology
- Biomarkers

Merck’s Focus:
- Anti-Inflammatory agents
- Biomarkers
- Vaccines
MERCK: GAP ANALYSIS, RESPIRATORY/ANTI-INFECTIVES SEGMENT (2012)

Product Line Gap (PLG) 4.25 Units
Distribution Gap (DG) 1.08 Units
Usage Gap (UG) 3.59 Units
Competitive Gap (CG) 66.77 Units
Current Sales (CS) 7.73 Units

Industry Market (IMP) 83.43 Units
Relevant Industry (RIS) 74.50 Units

IMP = PLG+DG+UG+CG+CS
IMP = 4.25+1.08+3.59+66.77+7.73
Real Market Share (RMS) = CS/RIS

TECHNOLOGY EVALUATION MATRIX: RESPIRATORY/ANTI-INFECTIVES SEGMENT ($B) (2012)

STRATEGY: ACQUISITION OF
NOVAVAX, INC.
ENVIRONMENTAL THREATS AND OPPORTUNITIES PROFILE: ACQUISITION OF NOVAVAX, INC.

Most Impactful Threats:
- Competition
- Politics

Most Impactful Opportunities:
- Social
- Technology
# ENVIRONMENTAL THREATS AND OPPORTUNITIES PROFILE (ETOP) FOR STRATEGY: ACQUISITION OF NOVAVAIX, 2013

<table>
<thead>
<tr>
<th>Factors</th>
<th>Impact of Factor</th>
<th>Importance of Factor</th>
<th>Environmental Threat/Opportunity</th>
<th>Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>Competition</td>
<td>-4</td>
<td>9</td>
<td>-36</td>
<td>1</td>
</tr>
<tr>
<td>Politics</td>
<td>-3</td>
<td>8</td>
<td>-24</td>
<td>2</td>
</tr>
<tr>
<td>Energy</td>
<td>2</td>
<td>4</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Economics</td>
<td>2</td>
<td>6</td>
<td>12</td>
<td>4</td>
</tr>
<tr>
<td>Spirit / Ethics</td>
<td>3</td>
<td>5</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Ecology</td>
<td>3</td>
<td>5</td>
<td>15</td>
<td>6</td>
</tr>
<tr>
<td>International</td>
<td>3</td>
<td>7</td>
<td>21</td>
<td>7</td>
</tr>
<tr>
<td>Social</td>
<td>4</td>
<td>9</td>
<td>36</td>
<td>8</td>
</tr>
<tr>
<td>Technology</td>
<td>5</td>
<td>10</td>
<td>50</td>
<td>9</td>
</tr>
</tbody>
</table>

**Total ETOP Score = 97**

Impact is ranked from -5 (strongly negative) to +5 (strongly positive). Importance if ranked from 1 (unimportant) to 10 (very important).

**Comments:** Competition is the greatest Threat for Merck’s acquisition of Novavax, due to the saturation of other biotechnology competitors, especially those developing pandemic and seasonal influenza vaccines. Politics is the second biggest Threat because of strict regulations by the FDA to ensure drug safety and effectiveness. However, the government has shown certain support for the development of pandemic influenza vaccines. Technology is the biggest Opportunity, as Novavax will provide Merck with innovative Virus-Like Particle technology to develop recombinant pandemic and seasonal influenza vaccines. This technology may allow Merck to elaborate effective and safe influenza vaccines, among other types of vaccines based on such technology. Social factors are the second biggest Opportunity as there is an increase in population, which is prone to be infected by the influenza virus, especially the elderly and the children.

CRITICAL ISSUES

• Merck does not currently have a program devoted to Biotechnology and would benefit from the acquisition of a company that would provide a product pipeline in the Biotechnology Industry

RECOMMENDED STRATEGIES

• For Merck, its researchers want to develop universal flu vaccines that go beyond cellular immunity and protection from challenge,\(^3\) as well as Seasonal influenza vaccines that have clinical data demonstrating differentiation from marketed products

JUSTIFICATION

• Novavax, Inc. has technological advances that have allowed it to make breakthroughs in gene therapy techniques that would open up Merck to entirely new product lines.

IMPLEMENTATION PLAN

- Investment from Merck’s Research and Development department would allow Novavax to build more of its smaller facilities, which due to its manufacturing in single-use bioreactor systems the economically sized labs can be distributed to regions that need a local supply of influenza vaccine.\(^4\)

- A Novavax VLP vaccine plant capacity of 75 to 100 MM doses could be built and commissioned for $35-40 MM within 24 months.
## FINANCIAL ANALYSIS

<table>
<thead>
<tr>
<th>Year</th>
<th>Change in Permanent Investment</th>
<th>Change in Net Working Capital</th>
<th>Cash Outflow</th>
<th>Depreciation</th>
<th>Net Income</th>
<th>Cash Inflow</th>
<th>Net Cash Flow</th>
<th>Cumulative Cash Flow</th>
<th>Discounted Net Cash Flow @ 10%</th>
<th>Discounted Cumulative Cash Flow @ 10%</th>
</tr>
</thead>
<tbody>
<tr>
<td>2013</td>
<td>967.00</td>
<td>14.56</td>
<td>967.00</td>
<td>42.17</td>
<td>(250.17)</td>
<td>(208.00)</td>
<td>(1,175.00)</td>
<td>(1,175.00)</td>
<td>(1,175.00)</td>
<td>(1,175.00)</td>
</tr>
<tr>
<td>2014</td>
<td>88.90</td>
<td>21.15</td>
<td>103.46</td>
<td>46.38</td>
<td>(267.38)</td>
<td>(221.00)</td>
<td>(324.46)</td>
<td>(1,499.46)</td>
<td>(294.96)</td>
<td>(1,469.96)</td>
</tr>
<tr>
<td>2015</td>
<td>80.14</td>
<td>15.55</td>
<td>101.29</td>
<td>50.56</td>
<td>(276.56)</td>
<td>(226.00)</td>
<td>(327.29)</td>
<td>(1,826.75)</td>
<td>(279.49)</td>
<td>(1,740.45)</td>
</tr>
<tr>
<td>2016</td>
<td>80.80</td>
<td>19.89</td>
<td>96.35</td>
<td>54.60</td>
<td>(288.60)</td>
<td>(234.00)</td>
<td>(330.35)</td>
<td>(2,157.10)</td>
<td>(248.20)</td>
<td>(1,988.65)</td>
</tr>
<tr>
<td>2017</td>
<td>65.97</td>
<td>151.45</td>
<td>85.86</td>
<td>57.88</td>
<td>(304.88)</td>
<td>(247.00)</td>
<td>(332.86)</td>
<td>(2,489.96)</td>
<td>(227.35)</td>
<td>(2,216.00)</td>
</tr>
<tr>
<td>2018</td>
<td>56.09</td>
<td>207.54</td>
<td>197.36</td>
<td>60.77</td>
<td>258.14</td>
<td>50.60</td>
<td>(2,439.37)</td>
<td>(31.42)</td>
<td>(2,184.58)</td>
<td></td>
</tr>
<tr>
<td>2019</td>
<td>47.76</td>
<td>29.25</td>
<td>242.28</td>
<td>63.20</td>
<td>305.48</td>
<td>228.48</td>
<td>(2,210.89)</td>
<td>128.97</td>
<td>(2,055.61)</td>
<td></td>
</tr>
<tr>
<td>2020</td>
<td>55.51</td>
<td>141.36</td>
<td>299.40</td>
<td>65.73</td>
<td>365.13</td>
<td>223.77</td>
<td>(1,987.11)</td>
<td>114.83</td>
<td>(1,940.78)</td>
<td></td>
</tr>
<tr>
<td>2021</td>
<td>43.50</td>
<td>106.43</td>
<td>358.29</td>
<td>67.70</td>
<td>426.00</td>
<td>319.56</td>
<td>(1,667.55)</td>
<td>149.08</td>
<td>(1,791.70)</td>
<td></td>
</tr>
<tr>
<td>2022</td>
<td>64.75</td>
<td>109.88</td>
<td>389.00</td>
<td>70.41</td>
<td>459.41</td>
<td>349.53</td>
<td>(1,318.02)</td>
<td>148.24</td>
<td>(1,643.46)</td>
<td></td>
</tr>
<tr>
<td>2023</td>
<td>54.02</td>
<td>190.03</td>
<td>454.70</td>
<td>72.52</td>
<td>527.22</td>
<td>337.19</td>
<td>(980.83)</td>
<td>130.00</td>
<td>(1,513.46)</td>
<td></td>
</tr>
<tr>
<td>2024</td>
<td>83.22</td>
<td>250.69</td>
<td>538.53</td>
<td>75.42</td>
<td>613.96</td>
<td>363.27</td>
<td>(617.56)</td>
<td>127.32</td>
<td>(1,386.14)</td>
<td></td>
</tr>
<tr>
<td>2025</td>
<td>69.31</td>
<td>183.34</td>
<td>637.96</td>
<td>78.44</td>
<td>716.40</td>
<td>533.06</td>
<td>(84.50)</td>
<td>169.85</td>
<td>(1,216.29)</td>
<td></td>
</tr>
<tr>
<td>2026</td>
<td>67.48</td>
<td>216.85</td>
<td>770.45</td>
<td>81.23</td>
<td>851.68</td>
<td>634.83</td>
<td>550.33</td>
<td>183.89</td>
<td>(1,032.41)</td>
<td></td>
</tr>
<tr>
<td>2027</td>
<td>88.74</td>
<td>262.67</td>
<td>909.25</td>
<td>84.50</td>
<td>993.75</td>
<td>731.07</td>
<td>1,281.40</td>
<td>192.81</td>
<td>(839.89)</td>
<td></td>
</tr>
<tr>
<td>2028</td>
<td>58.82</td>
<td>194.45</td>
<td>1,009.01</td>
<td>87.04</td>
<td>1,096.05</td>
<td>901.60</td>
<td>2,183.00</td>
<td>215.84</td>
<td>(624.06)</td>
<td></td>
</tr>
<tr>
<td>2029</td>
<td>93.92</td>
<td>353.94</td>
<td>1,188.10</td>
<td>90.54</td>
<td>1,278.64</td>
<td>830.78</td>
<td>3,013.78</td>
<td>180.80</td>
<td>(443.25)</td>
<td></td>
</tr>
<tr>
<td>2030</td>
<td>86.08</td>
<td>354.10</td>
<td>1,389.44</td>
<td>93.26</td>
<td>1,482.70</td>
<td>1,128.60</td>
<td>4,142.38</td>
<td>223.29</td>
<td>(219.97)</td>
<td></td>
</tr>
<tr>
<td>2031</td>
<td>84.55</td>
<td>289.16</td>
<td>1,677.98</td>
<td>53.90</td>
<td>1,731.88</td>
<td>1,442.72</td>
<td>5,585.10</td>
<td>259.49</td>
<td>39.52</td>
<td></td>
</tr>
</tbody>
</table>

CONCLUSION

• The potential acquisition strategy would be beneficial to Merck

• There are Potential Difficulties:
  • Control, Adaptability, and Organization
  • Work Load

• Merck should take a Competitive approach
BIBLIOGRAPHY